RE-BVS – Piemonte Repository

Sfoglia per AUTORE
COSCIA M
Collezione AO Cuneo

Items : 5

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. in British journal of haematology / Br J Haematol. 2025 Mar;206(3):924-929. doi: 10.1111/bjh.19976. Epub 2025 Jan 7.

2025
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Vitale C; Coscia M; Bruno B; Rambaldi A; Laurenti L; Krampera M; Gaidano G; Rivela P; Quaglia FM; Quaresmini G; Moia R; Innocenti I; Deodato M; Frustaci AM; Catania G; Montalbano MC; Perutelli F; Boccellato E;

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Penna G; Chiarenza A; Foà R; Derenzini E; Levato L; Orsucci L; Gottardi D; Gattei V; Gozzetti A; Gentile M; Sanna A; Olivieri J; Murru R; Stefoni V; Leone M; Baratè C; Marasca R; Malerba L; Ibatici A; Tisi MC; Chiurazzi F; Varettoni M; Del Poeta G; Marchetti M; Farina L; Giordano A; Foglietta M; Re F; De Paoli L; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. in Haematologica / Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.

2014
AO Cuneo

Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M;